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ABSTRACT 
 
Cardiac diseases are the leading cause of mortality in the United States, accounting for every one 
in seven deaths. There are a large proportion of cardiac diseases that need histopathological 
examination by pathologists for a conclusive diagnosis, but this technique hasn’t been improved 
upon in the past decade. In this work, we have attempted to advance the current state of histology 
by developing stainless staining protocols using infrared spectroscopy. 
 
The current gold standard to identify cardiovascular complications such as ischemia, fibrosis, 
alcoholic cardiomyopathy and transplant rejection is biopsy followed by histology. This 
approach lacks in many aspects. Major challenges faced by pathologists are: addressing inter-
observer variability and experimental variations in stain development, and developing 
approaches for in-situ histopathology. Specifically, in the case of cardiac transplants, regular 
monitoring of the transplant is required in order to ensure that the body accepts the transplant. 
This is done by collecting tissue biopsies at specific time intervals. The presence of lymphocytic 
infiltration and accompanying fibrosis is indicative of transplant rejection. A prompt clinical 
action is required if rejection is identified in the biopsy. Cardiac transplant patients can benefit 
from techniques that can identify lymphocytic infiltration and fibrosis with high accuracy, 
complementing current pathology practice and giving greater opportunity to pathologists to study 
complex cases. In the first part of this work, we used infrared spectroscopy coupled with 
supervised Bayesian classification to identify lymphocytic infiltration and fibrosis in the 
myocardium in endomyocardial biopsy samples. This classifier was robust and could be easily 
applied to identify lymphocytes in the tissue and to differentiate between fibrosis in endocardium 
with fibrosis in myocardium which stains similarly in hematoxylin and eosin stain (H&E).  
 
Repeated biopsy procedures can cause significant trauma to the patient, and often the surgeons 
require real time histopathology information of the tissue during surgeries. This cannot be 
accomplished by traditional histology where the tissue sample needs to be excised, sectioned 
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and stained for analysis. Since infrared spectroscopy in stainless, probe-based instruments can 
be developed to provide detection in-situ but were earlier limited by the speed of imaging using 
Fourier Transform infrared spectrometers. The problem of speed can be overcome by using 
quantum cascade laser-based discrete frequency infrared (DFIR) imaging instruments. In the 
second part of this work, we analyzed data collected on recently developed discrete frequency 
instruments and compared it to data collected on FT-IR imaging instruments. This was done by 
unsupervised data clustering to observe histological classes in both types of data. 
 
After establishing that the data collected in DFIR mode retained spectral differences between the 
histological classes to enable their differentiation, in part three of this work we have done 
extensive analysis of classification approaches that can be applied to the DFIR data. This study 
will be relevant to many of the previously built Bayesian classification models that need to be 
evaluated for their applicability on data collected in discrete frequency mode. In addition, we 
identified specific spectral features that could be used to differentiate between fibrosis and 
normal tissue in cardiac biopsy samples computationally at high speed using discrete frequency 
approach. This can give way to utilization of this model in fiber optic probe-based technology 
for on-site detection of fibrosis in patients. 
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INTRODUCTION 
Prospects for Chemical Imaging in Cardiovascular Pathology 
Abstract 
Vibrational Spectroscopy is a well-established technique that utilizes light waves to delineate 
chemical signatures of samples. The molecular basis of the approach has been well-established 
for small chemicals and understanding for complex biomedical samples is emerging. In 
particular, the availability of high-performance and low-cost computation capabilities are now 
transforming spectroscopic delineation of cellular characteristics in various tissues. This review 
describes the emergence of this technology and the role it may play in the development of a new 
way for cardiac tissue assessment at a chemical, molecular and cellular level. The promise in the 
cardiovascular arena is highlighted with emphasis given to ongoing developments that may 
transform cardiovascular pathology and imaging. 
 
Current Evaluation of Cardiovascular Diseases and the Need for New Technology 
Cardiovascular diseases are the leading cause of mortality in the United States accounting for 
every one in 7 deaths in the US1. Cardiovascular diseases broadly fall into those affecting 
coronary arteries, valves, cardiac muscle, cardiac rhythm and aortic & vascular structures.  There 
is often overlap of some of these disorders. Patients are frequently imaged through a variety of 
modalities, which include coronary angiography, echocardiography, computed tomography, 
magnetic resonance imaging, nuclear scans, conventional x-rays, depending on the type of 
disorder.  However, certain conditions such as diseases affecting the cardiac muscle 
(cardiomyopathies), cardiac valves (calcification, degeneration, fibrosis, myxomatous changes, 
infections), cardiac transplant rejection (after heart transplantation), cardiac ischemia/infarction 
(definitely differentiating between ischemia, infarction, scarring) have been very difficult to 
diagnose accurately in patients without pathological studies. The use of histopathological 
examination is confirmatory and the final arbiter in making diagnoses. However, this is 
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complicated and requires excision or removal of the affected tissue, tissue processing, use of 
multiple stains and evaluation by experienced pathologists.   
The Case for Better Cardiac Assessment 
Since the heart is not easily accessible for biopsy, catheter-based techniques have been used to 
excise small fragments of cardiac tissue, typically from the right ventricle and sometimes from 
the left ventricle.  In the absence of open biopsy of the heart, this is the gold standard for 
pathological diagnoses.  Cores of left ventricular apical muscle during ventricular assist device 
implants, small off-cuts of outflow tract myocardium in patients undergoing surgical myectomy 
for HOCM, resected segments of right ventricular muscle in the repair of Tetralogy of Fallot may 
represent some of the available pathological specimens for analyses. 
All of these are invasive to the point of some excision. Non-invasive methods such as 
angiography, Magnetic resonance imaging (MRI), echocardiography, Computed tomography 
(CT) scanning, Nuclear Scans show promise but may not correlate with actual pathological states 
in many conditions. The gold standard continues to be a histopathological evaluation of heart 
tissue through excisional biopsies of some sort. All of these tests are typically performed as a 
reactive measure when the patient has symptoms of cardiovascular diseases.  
Imaging for CVDs  
A variety of clinical tools are used for the assessment and prediction of cardiovascular diseases. 
Important elements of such tools are described here.  
Imaging: Imaging has traditionally been used to identify problematic areas after symptoms have 
been identified. A number of imaging modalities, such as MRI for assessing ischemic heart 
disease2–7 and more recently for quantifying  ventricular volume for assessing cardiac function8 
, PET/CT , and SPECT/CT have been used for diagnosis of coronary artery diseases 9–13 and for 
evaluation of myocardial perfusion14,15.  
Risk factors: Cardiovascular diseases have well-known risk factors among patient populations. 
For example, conventionally accepted factors such as patient’s age16, family history, dietary 
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habits, activity levels, diabetes17, history of smoking, hypertension, and obesity18,19; and more 
recently recognized new generation risk factors such as triglycerides, modified LDL and 
fibrinogen and levels of C-reactive protein18,20.   
Protein-based biomarkers: Most cardiovascular diseases are progressive and thus, early 
monitoring and prevention is a viable option for reducing mortality rates. It has been suggested 
that identification and use of biomarkers related to changes occurring at the molecular stage, 
before the disease has started showing symptoms can predict the occurrence of disease and 
outcome21,22. Inflammatory markers23 such as C-reactive protein levels, IL-6, TNF α and IL-10 
have been studied as predictors for heart disease risk24–28. Blood tests to assess the risk of venous 
thrombosis and identify possible coagulation of the cardiovascular system have been suggested 
using markers such as elevated concentrations of factors II, VIII, IX, XI, and fibrinogen29–32. 
Proteins that are present in the heart cells and released after a heart attack, such as Creatine 
kinase, Myoglobin, Cardiac troponin I etc. can also be measured in the blood to identify 
myocardial damage33. A thorough table enlisting available blood-based tests for heart diseases 
can be referred to elsewhere33.   
Genetic predisposition: Several genetic abnormalities have been found to be associated with an 
increased risk of developing cardiovascular disease34,35. For example, genetic variation in the 
lipoprotein A locus is associated with aortic valve calcification36; rare de novo copy number 
variations 37,38and mutations in GATA4 and TBX539 present genetic loci for congenital heart 
disease. Multiple epigenetic modifications have also been identified that can result in cardiac 
distress and malfunctions40–42.   
Despite major advances in assessing risk and occurrence of cardiovascular diseases, pathology 
remains a holdout. In cases requiring histological analysis of tissue, anatomical and physiological 
changes in diseased states are used. The two major needs are (a) addressing the difficulty of 
diagnoses in cases, (b) adding molecular information and (c) measuring in situ, living tissue. To 
address these needs, there are imaging techniques which can probe at the molecular level and 
identify changes at cellular level much before they are identifiable through conventional 
techniques.  Through molecular imaging, specific molecules, variations in tissues and 
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extracellular spaces can be identified that could start at the early onset of the disease. In addition, 
precise identification of the problem at the micro level can enable practitioners to tailor treatment 
on case by case basis, enabling personalized care.  
 
Molecular imaging for the assessment of cardiovascular diseases 
Contrast agent based imaging: Contrast agent based imaging has enabled in vivo probing of 
abnormalities with currently available imaging modalities. Many developments in this direction 
have been enabled by emerging nanotechnology-based contrast agents43,44. Contrast agents for 
positron emission tomography (PET) scanning, for example, 18F-FDG have gathered interest as 
a prospective marker for identification of inflammation45–47.  However, the clinical applicability 
of this technique is limited by myocardial uptake of FDG that gives significant signal during PET 
imaging48 and efforts are underway to optimize vessel wall imaging using FDG49,50.  
Gadolinium-based contrast agents have been used to target specific sites for detection with 
MRI51. These paramagnetic nanoparticles can get localized to fibrin clots giving high T1 
weighted contrast52. However, safety concerns arise when using Gd-based contrast agents due to 
the risk of nephrogenic systemic fibrosis53. To counter these, biodegradable polydisulfide 
dendrimer nanoclusters containing Gd54 and  Manganese based contrast agents are being 
developed that are expected to reduce such risks55.  Enhanced uptake of superparamagnetic iron 
oxide (SPIO) nanoparticles by macrophages has been utilized for identifying macrophage 
localization. However, a clinical trial utilizing ferucarbotran (Resovist®) did not show any 
further improvement in visualization of myocardial infarction as compared to the conventional 
Gd-based imaging modalities56. MRI has also emerged as a potential noninvasive technique for 
detection and quantification of vascular remodeling using elastin-specific MR contrast agents, 
for which animal models have been studied57.  Here we have given a short summary of some of 
the recent developments, readers are referred to specific review articles for an in-depth discussion 
of targeted molecular imaging agents in the nano and micro size range utilizing conventional 
imaging modalities43,58. 
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Label-free imaging of biological samples: Traditionally, researchers have relied on externally 
applied contrast agents, such as dyes and fluorescent probes for identification of cell types. In 
vivo diagnostic tests for many cardiovascular diseases, on the other hand, have utilized the 
changes in cardiac function to identify the problem using noninvasive techniques. 
Electrocardiographic (ECG) tests have been long established to assess the electrical activity of 
the heart and it has been shown that abnormal ECG can be associated with an increased risk of 
coronary heart disease(CHD) events 59–61 but its utility to predict CHD in asymptomatic adults 
has not been established yet62. It has been difficult to probe at the molecular level in terms of 
disease diagnosis owing to the limited sensitivity of CT and MRI and limited penetration depth 
of optical imaging techniques. Conventional techniques have been very effective in the 
management of a multitude of cardiovascular diseases and do not require extensive 
modifications. However, amid studying biophysical properties of the tissue/organ and applying 
the molecular imaging technique for diagnosis by histopathology, there remains a gap between 
estimation of disease at the surgery table and diagnosis in the pathology lab. The motivation 
behind developing automated label-free diagnosis techniques is to fill this gap and bring real-
time pathology on site. In the following sections of this article, we demonstrate the application 
of recently developed technology of quantum cascade laser-based infrared imaging for 
developing automated pathology of cardiovascular diseases and its potential for clinical 
implementation.     
Spectroscopy and its applications in cardiovascular diseases 
Spectroscopy pertains to the study of absorption and emission of light waves as it interacts with 
matter. Various spectroscopic techniques have been utilized in past to probe the structural and 
biochemical properties of samples based on the wavelength of light used as the probe. Light of 
radio wave frequency, for example, has been a prime tool for studying molecular structure 
through magnetic resonance imaging. While near-infrared probes and fluorescence imaging has 
been explored in great details in past63–72, optical spectroscopy techniques such as infrared 
spectroscopy and Raman spectroscopy have not been discussed. Supplementing already 
developed techniques which can assess myocardial blood flow or perfusion64,73,74, these 
techniques are particularly useful for molecular imaging of targets and have become popular to 
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identify and understand biochemical changes taking place in tissues. Here we will briefly discuss 
current progress in utilizing these techniques for identification of cardiovascular diseases.  
Principles of chemical microscopy and recent enabling advances 
Mid-infrared spectroscopy and Raman spectroscopy enable chemical microscopy in the sense 
that they can quantify chemical constituents and map it on the tissue slide. Therefore, vital 
macromolecules such as collagen proteins, nucleic acids, and glycogen levels can be analyzed 
and their distribution of tissue can be assessed. Therefore, these techniques have four-fold 
potential in assessing cardiovascular diseases. First, mid-infrared chemical imaging can assess 
collagen level variations in tissue which is correlated with fibrosis. Second, high glycogen levels 
in tissue are indicative of early ischemia. There is no established way to observe this elevation 
on tissue section currently but is possible through chemical imaging. Third, apart from 
identification of high collagen and glycogen levels, infrared microscopy can utilize variation in 
multiple chemical species present in tissue to digitally stain the tissue without the need of stains. 
It is, therefore, possible to identify different cell populations present in a tissue section, enabling 
identification of many cardiovascular diseases, for example, transplant rejection. Fourth, digital 
pathology data obtained through chemical imaging can be integrated with patient data such as 
age, weight, and various risk factors to give a personalized diagnosis and prediction of disease 
outcome. This makes chemical imaging the next generation smart imaging and detection 
technique with vast potential remaining to be tapped.  
Raman spectroscopy 
A detailed review has already been written discussing Raman spectroscopy and utilizing it for 
detection of transplant allograft rejection75. In addition, since myocardial infarction and 
subsequent repair causes significant biochemical changes, it is also possible to observe these 
changes through Raman spectroscopy76. Damage in collagen fiber regions can be analyzed in 
nondestructive manner77 and many metabolites such as glucose, cholesterol and lipids can be 
assessed in the blood which are known risk factors associated with atherosclerotic cardiovascular 
diseases78. A recent study reported high specificity (greater than 98%) and high sensitivity 
(greater than 96%) in the identification of normal, necrotic, granulated and fibrotic tissue 
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obtained from rats, establishing label-free Raman spectroscopy to evaluate myocardial 
infarction79. This technique has also been used in past to diagnose coronary atherosclerosis80–83. 
Through optical fiber-based probes, Raman spectroscopy can be used to identify atherosclerosis 
and monitor its progress, predict plaque rupture and determine therapy83,84 and such a method 
can be useful in stainless probing of diseases in situ using Raman spectroscopy. 
Mid-infrared spectroscopy 
Mid-infrared spectroscopy based disease recognition has been applied in two major 
cardiovascular fields in past. First is assessing calcifications and characterizing atherlosclerotic 
plaques to determine vulnerable plaques. In one study, mechanism of aortic valve calcification 
was elucidated using infrared spectroscopy which showed that amorphous calcium phosphate 
salts could be detected using infrared spectroscopy which was not analyzable through X-rays85. 
In addition, qualitative and quantitative measurement of lipid content, as well as changes in 
protein structure in atherosclerotic plaque, can be performed using infrared spectroscopy86–88. 
The water content in tissue can cause strong absorbance in the IR spectrum when tissue is imaged 
in situ, but water subtraction algorithms can be applied to remove its contribution to characterize 
atherosclerotic plaques89,90.  
In the second approach, changes in myocardium pertaining with lipids, proteins, and collagen 
content have been studied using infrared chemical imaging. Wang et al91 studied hamster models 
to identify differences in inflammatory response between immune resistant and immuno-
permissive mouse models and identified chemical differences between the two in terms of 
lipid/protein ratio and collagen content. Another study utilized rat models to study collagen 
deposition post myocardial infarction and identified a strong correlation between FT-IR data and 
trichrome stain as well as immunohistochemical staining of collagen type I92. Studies cited above 
and others93 show that extracellular matrix components such as collagen and elastin are crucial 
to identifying many cardiovascular diseases. Probe-based IR imaging instruments are already 
being developed and tested on animal models to quantify collagen levels which pave way for in 
situ studies94. 
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Impressive progress has been made in the identification of abnormality in tissues, but such 
developments have not been sufficient for clinical translation due to (a) the need of high accuracy 
and (b) ability to image tissue comparable to the gold standard of histopathology. Many in vivo 
techniques have been developed but they fail on the first count and cannot accomplish the second. 
In some cases, point based detection suffices, but nevertheless, capabilities to perform imaging 
need to be developed further as they form the basis for future with much greater information 
content and ability to integrate patient data for greater diagnostic and prognostic accuracy.  
In a past study published from our lab, we identified and digitally stained lymphocyte infiltration 
and fibrosis in endomyocardial biopsy samples from cardiac transplants95. Using infrared 
spectroscopy, high accuracy was obtained when the stain was compared to the pathologists’ 
interpretation of H&E stain. In terms of utility, infrared imaging based stains can significantly 
reduce the sources of false positives and false negatives during the analysis that can arise from 
human errors in sample handling, preparation and interpretation. In past, the chief concern in 
translating this idea to clinics was the speed limitation of conventional infrared imaging systems. 
However, with the advent of quantum cascade laser (QCL) imaging instruments, imaging 
specific bands to probe molecular information has become at least 10 times faster. In recent tests 
conducted in our lab, we found that high accuracy was retained when using QCL for imaging 
cardiac biopsy samples (unpublished results). This is a huge leap in terms of how samples are 
analyzed and interpreted currently, and the hope is to develop next generation imaging techniques 
for rapid detection of diseases using inherent tissue chemistry. Our findings also open up paths 
to faster and accurate histological analysis of tissues, bringing us closer to the goal of intra-
operative and in-vivo imaging.  
In conclusion, infrared based chemical imaging has seen major advancements recently with a 
potential to grow much more. An integrated solution has to be made by jointly considering the 
benefits and limitations of current and oncoming technologies. A major advantage offered by 
infrared spectroscopy is the chemical signature of tissue which can be used in conjugation of 
existing technologies to give a greater level of information associated with the sample. Touch 
based probes, while in their infancy are being tested and would soon become accessible to the 
clinics with well-developed computational protocols. Along with capabilities of integrating 
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patient information and capability of assessing tissue damage real time, this makes infrared 
spectroscopy a strong candidate for assisting surgeons using intraoperative probes.  
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CHAPTER 1 
Computational Imaging for Cardiovascular Pathology: Chemical Microscopic Imaging 
Accurately Determines Cardiac Transplant Rejection1 
 
Abstract  
Rejection is a common problem after cardiac transplants leading to significant number of adverse 
events and deaths, particularly in the first year of transplantation. The gold standard to identify 
rejection is endomyocardial biopsy. This technique is complex, cumbersome and requires a lot 
of expertise in the correct interpretation of stained biopsy sections. Traditional histopathology 
cannot be used actively or quickly during cardiac interventions or surgery. Our objective was to 
develop a stain-less approach using an emerging technology, Fourier transform infrared (FT-IR) 
spectroscopic imaging to identify different components of cardiac tissue by their chemical and 
molecular basis aided by computer recognition, rather than by visual examination using optical 
microscopy. We studied this technique in assessment of cardiac transplant rejection to evaluate 
efficacy in an example of complex cardiovascular pathology. We recorded data from human 
cardiac transplant patients’ biopsies, used a Bayesian classification protocol and developed a 
visualization scheme to observe chemical differences without the need of stains or human 
supervision. Using receiver operating characteristic curves, we observed probabilities of 
detection greater than 95% for four out of five histological classes at 10% probability of false 
alarm at the cellular level while correctly identifying samples with the hallmarks of the immune 
response in all cases. The efficacy of manual examination can be significantly increased by 
observing the inherent biochemical changes in tissues, which enables us to achieve greater 
diagnostic confidence in an automated, label-free manner. We developed a computational 
pathology system that gives high contrast images and seems superior to traditional staining 
                                                          
1 Reprinted, with permission, from Saumya Tiwari, Vijaya B. Reddy, Rohit Bhargava, and Jaishankar Raman. "Computational Chemical 
Imaging for Cardiovascular Pathology: Chemical Microscopic Imaging Accurately Determines Cardiac Transplant Rejection."PloS one 
10, no. 5 (2015): e0125183. doi:10.1371/journal.pone.0125183 
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procedures.  This study is a prelude to the development of real time in situ imaging systems, 
which can assist interventionists and surgeons actively during procedures. 
Introduction  
The success of cardiac transplantation depends foremost on the immune response to the new 
implant1. The gold standard for identifying allograft rejection is endomyocardial biopsy (EMB)2. 
Endomyocardial biopsy section from a normal heart consists mostly of myocardium which is 
unoriented and appears red-tan. The tissue section is bordered by the overlying endocardium 
which is pearly white in appearance3. In case of cardiac transplant, an activation of the immune 
system can cause severe inflammation which can result in transplant rejection and eventual death 
of patient. Grade of acute cellular rejection, as defined by the revised ISHLT (International 
Society for Heart & Lung Transplantation) heart biopsy grading scale4 is determined by the 
presence of infiltrate and associated myocyte damage. Grade 0 signifies no rejection while grade 
2 (mild rejection), 3 (moderate rejection) and 4 (severe rejection) requires assessing the number 
of foci of infiltrate and associated myocardium damage. Prolonged tissue damage, which could 
be a result of immune attack, injury or toxins etc. may result in deposition of extracellular matrix 
components at the site of damage, leading to a condition termed as fibrosis5-7. Such an 
observation of fibrosis is important in assessing myocardium damage in case of allograft 
rejection. For a detailed description of histopathology associated with cardiac allograph rejection, 
the readers are directed to available literature3-5.  
In routine cases of monitoring allograft reception, biopsy sections are stained and the 
inflammatory response is observed, which is predominantly lymphocytic3. This approach suffers 
from inter-observer variability and an inability to quantify accuracy and confidence in data8-9. 
The estimation variance complicates decision-making. For example, misinterpretation of fibrosis 
through the sub-endocardium can give the erroneous impression of extensive fibrosis2 and can 
cause false positives. The subjective nature of histopathological assessment and the apparent 
potential for errors has long been recognized and debated upon10-11. This has led to development 
of immunohistochemistry for diagnostic purposes by evaluation of specific biomarkers11-12 but 
this technique can get affected from variations in sample preparation, fixation procedures, 
antibody specificity and similar other experimental details12 .There is a need, therefore, to explore 
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technologies that can make routine histopathological examinations more accurate, consistent, 
facile and reliable.  
As opposed to the standard practice of staining tissue with dyes or molecular imaging of specific 
epitopes, the emerging technology of chemical imaging can utilize the inherent molecular 
contrast within samples to provide histologic data. One approach in particular, infrared (IR) 
spectroscopic imaging, offers strong contrast, high sensitivity and rapid data recording. It has 
shown potential broadly in biomedical applications for understanding metabolomics and 
molecular diagnostics13-14. Combined with computer algorithms, IR imaging has been used for 
differentiating between diverse cell types in tissues and for detecting disease15-17. Several studies 
related to cardiovascular systems have reported spectral analysis of tissue and disease in terms 
of resulting biochemical changes. Infrared imaging has been used to study calcifications in aortic 
valve18, for characterizing heart valves19, studying diabetes induced changes in myocardium and 
vessels20-23, for analyzing cardiac extracellular matrix (ECM) remodeling24; and ECM and serum 
components following myocardial infarction25-28. While these studies successfully demonstrate 
differentiation between diseased and healthy tissue via lipid and protein composition and 
collagen content, a histologic analysis consistent with existing pathology practice is lacking. 
Characterization of atherosclerotic plaques29-35 is a step towards clinically-actionable 
information. However, a practical assay to diagnose conditions and provide actionable 
information is still lacking. One step in this direction is to utilize digital information obtained 
from FT-IR spectroscopy and develop a classification protocol which can assign cell identifier 
value to each pixel on the tissue image. Such classification systems, which require multivariate 
analysis have been attempted for identification of various cell types in cancer but very little work 
is found in diseases related to heart36-37. Specifically in case of identification of cardiac allograft 
rejection, we require an automated detection system that has ability to distinguish not only 
between different cell types but more importantly correctly identify lymphocytes. Identification 
of lymphocytes is also critically needed as it has potential importance in assessment of many 
more diseases, for example, identification of tumor infiltrating lymphocytes is also of great 
interest, and a recent study has sought to identify lymphocytic signature in peripheral blood 
samples38. Another study has utilized unsupervised clustering algorithm to obtain impressive 
identification of B and T cells in a single patient sample using infrared spectroscopy39. However, 
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when analyzing multiple patient samples, accounting for point-to-point variations in the samples 
and across samples is difficult via unsupervised classifications, leading to reduction in accuracy.  
The work presented in this manuscript takes this goal of identifying lymphocytes one step further 
by classifying infiltrating lymphocytes spatially in a biopsy section using supervised 
classification algorithms of infrared spectroscopy data. Given the complexity and expertise 
required when conventional pathology is used to diagnose transplant rejection in the heart, we 
used chemical imaging to see if it could provide the necessary diagnoses and visualizations useful 
in clinical practice. We utilized differences in the infrared absorbance patterns among different 
histological classes to develop an automated system where the digital input of IR spectroscopy 
data yielded a computationally colored image showing different classes similar to what one 
would obtain using rigorous staining procedures. 
 
Materials and methods 
 
Sample procurement  
Written consent was obtained in all patients for study of their archived pathological specimens. 
The consents were recorded and maintained securely and separately. The consent process for this 
study was reviewed by the IRB at Rush University Medical Center and approved. All specimens 
were anonymized, de-identified and no clinical or demographic information was recorded. Thirty 
five anonymized human EMB sections from ten patients, formalin fixed and paraffin embedded 
were examined. The biopsies were taken using a bioptome, which is an instrument inserted 
through the internal jugular vein, and directed under fluoroscopy to be positioned in the right 
ventricle. The biopsies are then taken as small pieces of tissue, typically measuring 1 mm x 1 
mm x1 mm. The section thickness was 5µm. Of the thirty five sections obtained; three sections 
had to be discarded due to damage to the sections. Out of the 10 patients analyzed, patient 1-5 
had no rejection; thus counted as control. Patient 6, 7 and 8 had moderate rejection; and patient 
9 and 10 had mild rejection. In current practice, it is very rare to find samples with grade 4 severe 
rejection, and hence such samples could not be included in the study.  
25 
 
 
Sample preparation 
Samples were microtomed onto reflective low-emission (Low-E) glass slides for IR imaging. 
These slides provide a reflective substrate for the sample in IR light but are transparent to visible 
light. Although when using Low-E slides, the IR beams pass through the sample twice and suffers 
from distortions in the spectrum40-41, we have observed that standard preprocessing and treatment 
of data yields good classification results without performing rigorous corrections for distortions. 
Albeit using substrates like Calcium Fluoride and Barium Fluoride is preferable, Low-E slides 
are inexpensive and easy to maintain, making them more practical in clinical environment.   
Prior to acquiring IR data, paraffin was removed from the samples by washing them twice with 
hexane and immersion in hexane for 14 hours at room temperature with continuous stirring. 
Removal of paraffin was evident from the reduction of paraffin-associated CH bending peak at 
1464cm-1 (fig. 1). Furthermore, the spectral features used in our analysis were extracted from 
regions which are not affected by paraffin vibrational modes to ensure that any residual paraffin 
did not interfere with results.  
Fourier transform infrared imaging 
De-paraffinized sections were imaged under mid-infrared light on the IR imaging system. FT-IR 
imaging was performed using a Spotlight 400 system from Perkin Elmer. Spectra were collected 
using a liquid nitrogen cooled mercury-cadmium-telluride (MCT) 16-element 
linear array detector. The background was collected on a clear area of low-E slide at 4cm-1 
resolution using 120 scans for each sample. All images were acquired in reflection mode with 
6.25 µm x 6.25 µm pixel size and 4 cm-1 spectral resolution with 2cm-1 step size using a single 
interferometer scan with signal to noise ratio (SNR) exceeding 500:1 in all cases. Data was 
collected over the mid-infrared region and truncated for storage (800cm-1 to 4000cm-1). The 
image resolutions were nominally 6.25 µm and 25 µm. Since the samples were large, (smallest 
dimension being at least 500 µm for every section) and irregularly shaped, each image was 
acquired by breaking it down to 5-10 smaller rectangular regions and using raster scanning of 
these parts. Each region was separately focused by the instrument to remove any error due to 
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change in focus and the composite image was stitched back together using ENVI-IDL 
4.8(Environment for Visualizing Images-Interactive Data Language). Processing time for a 
square section of 1mm X 1mm at 6.25 µm, starting with imaging and obtaining computational 
stain was about 2 hours. Processing time for the same section at 25 µm was about 10 minutes. It 
has to be kept in mind that this imaging was performed by sweeping through all the wavenumber 
bands from 4000 cm-1 to 800 cm-1 at 4 cm-1 resolution. After building the classifier, one can 
realize that only a segment of this range is actually necessary for classification (discussed in 
results), and thus scanning at discrete frequencies for detection can enable reduction in imaging 
time by three folds or larger42-43.  
 
Hematoxylin and Eosin (H&E) staining 
Serial sections were preserved and stained with H&E for initial determination of rejection grade 
by the pathologist. In addition, after IR imaging was performed on sections, the sections on low-
E slides were stained with Hematoxylin and Eosin stains for future comparisons and imaged 
using Zeiss visible microscope. All the data analysis done in this manuscript used H&E images 
from same section imaged by infrared spectroscopy and not serial section. 
 
Data analysis 
Data pre-processing: Acquired data were imported in ENVI-IDL 4.8 software for analysis. A 
figure annotating important IR peak assignment is shown in supplementary figure 1. A very 
comprehensive table of band assignments of IR spectra of heart tissue is given in this study20 
which can also be referred to. Throughout the analysis, we excluded pixels without protein-
characteristic Amide I absorbance since all cells and ECM in this tissue will contain protein (see 
fig. 1). This was done by setting a threshold of minimum absorbance value corresponding to an 
absorbance of 0.30, which is at least 10-fold larger than the peak-to-peak noise in the data.  
Identification of histological features (classes): With the aim of understanding spectral 
differences in various components of the section and in order to build a Bayesian classifier for 
27 
 
automated classification of the sections, we first built a classification grid comprising of 16 
sections by combining data from 16 images in a single file. The breakdown of 16 chosen sections 
for classification training set was as follows:  3 sections from patient 1, 2 sections each from 
patient 5, 6,9,10 and 1 section each from patient 2, 3, 4, 7, and 8. Sections were chosen to 
sufficiently represent each class, namely Myocardium, Endocardium, Fibrosis (Endocardium), 
Fibrosis (Myocardium) and Lymphocytes and to provide maximum inter-patient diversity to the 
training set. Remaining sections were used for validation set. The breakdown of validation set 
was as follows: 2 sections each from patient 3, 4, 5, 6, 7, 8, and 9 and 1 section each from patient 
1 and 10.  
We then used the peak height of vibrational mode at 1236 cm−1 to see contrast between 
lymphocytes and muscle. The 1236 cm-1 peak is associated with CH2 wagging vibrations 
associated with proteins44-45; which was found to be useful in prima facie differentiation of 
different classes (see fig. 2). Five histological classes, namely, Myocardium, Endocardium, 
Fibrosis (Endocardium), Fibrosis (Myocardium) and Lymphocytes were considered for our 
analysis. After H&E staining of samples, regions were marked by pathologist as the above classes 
and this annotation was considered as gold standard46. Next, exact same regions were marked in 
IR images by comparison with pathologist-annotated H&E images from same sections. Care was 
taken to mark only those regions which clearly belonged to a particular class as seen from H&E 
images (gold standard, as described earlier46). This process yielded approximately 330,000 
spectra for training the classification algorithm. For each of the classes, a linear two point 
correction across peaks of interest or specific peaks was used. The points were fixed for all 
spectra in the sample. Spectra were normalized to amide I peak (1652 cm-1) to account for the 
variations in sample thickness47. We then extracted average spectra for each class, which is 
shown in fig. 1.  
 Bayesian classification algorithm: Our Bayesian classifier works by determining the likelihood 
that an unknown pixel belongs to a particular class by using biochemically significant features 
called metric parameters defined by the user. Each of these parameters can have different weights 
in the classification process depending on their ability to differentiate between classes. We used 
a protocol that has previously been established and validated44,48,49. Using the spectral differences 
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observed among the classes in training set (shown in fig. 1), we defined a set of 217 parameters 
using four types of spectral metrics (peak height ratio, peak area to height ratio, peak area to area 
ratio and center of gravity) to differentiate each class from the others. To begin with, normalized 
peak heights are considered as parameters for all peaks appearing in absorbance spectrum using 
peak height ratio with amide I peak. Next, other quantities, peak area to height ratio, peak area 
to area ratio and center of gravity are defined as metric parameters using peaks in the spectra by 
manual examination of the differences in spectra between classes. This gave us 217 metric 
parameters to analyze data with. The significance of these metrics is to reduce data to significant 
quantities which is readily analyzable44.   
Use of ratios instead of absolute values also ensures that these metric definitions are independent 
of variability in instrumentation and sample preparation steps. We evaluated these metrics in 
terms of their ability to separate the classes by using minimum error in identification of class and 
the area under the curve (AUC) for the Receiver Operating Characteristic (ROC). We further 
tested the Bayesian classifier built using these parameters on an independent set of sections to 
evaluate its accuracy in identification of classes. The findings are described in the following 
section. 
Results and discussion 
 
Training 
Samples were imaged using IR microscopy and correlated to features in H&E images that were 
marked by the pathologist’s review as the ground truth. Computerized pattern recognition of IR 
imaging data from unstained EMB samples led to every tissue pixel being classified into a 
specific histological class. Compared to the ground truth, the resultant probability of detection at 
the pixel level for the training set was quite high for lymphocytes (0.991), fibrosis-endocardium 
(0.999), fibrosis-myocardium (0.997) and myocardium (0.952) and somewhat lower for 
endocardium (0.860) with approximately 0.10 probability of false alarm (fig 3 (i)). There is a 
probability of confusing fibrosis with endocardium as evident from confusion matrix shown in 
table 1. As can be seen, 48.5% of the tissue identified as endocardium by the pathologist was 
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classified as fibrosis in myocardium and 9.1% of the endocardium was identified as fibrosis in 
endocardium.  It is well known that the nature and structure of endocardium is not well visualized 
with conventional pathological methods.  This may be due to endocardial damage caused by the 
bioptome and the fact that endocardium is a very thin layer that is easily washed away during 
preparation. The lower accuracy in this data set also arises from a limited number of endocardium 
pixels, as partly mitigated by having higher number of pixels in validation set (supplementary 
table 1). The issue of endocardium damage during biopsy is unfortunately out of our control. The 
nature of the biopsy is such that as the bioptome is used along the endocardial surface of the right 
ventricle, there is inherent damage to the endocardium. This coupled with the fact that the 
endocardium is a thin, evanescent layer that is easily damaged/disturbed makes endocardial 
evaluation difficult. Therefore, we have not discussed any precautions for sample preparation. It 
is important to remember that findings pathognomonic of transplant rejection are not manifested 
in the endocardium but in the sub-endocardial tissue and in the myocardium. Since our focus 
here was the identification of transplant rejection, future efforts can be undertaken to refine the 
data and potentially improve efficiency by better capability instruments for enhanced spatial 
resolution and faster imaging time. Focused efforts to collect specific tissue components, such as 
endocardium would give us sample size large enough to accurately characterize these 
components.  
  
Validation 
We performed validation using an independent set of 16 samples with approximately 300,000 
pixels. Uniformly high probability of detection with low probability of false alarm (0.13) was 
found (fig 3(ii)). Comparison of our technique with H&E staining is shown in fig. 4; and 
comparison from different grades of rejection has been shown for boxed areas from figure 4 in 
Supplementary figure 2. Probability of detection at 10% probability of false alarm is provided in 
table 2. While achieving significant accuracy, our approach is likely limited by mixed pixels 
(particularly in regions of lymphocyte infiltration; which is strongly associated with myocyte 
necrosis and fibrosis) and inclusion of boundary pixels. This limitation is also reflected in 
identification of endocardium for which we do not have comparatively good representation of 
30 
 
pure pixels.  Endocardium was not easily visible in the pathology specimens either.  While pixel 
level accuracy may be improved, we achieved accurate identification of the key histopathologic 
features for decision-making in every sample. Hence, we sought to examine if accurate 
information could be achieved by speeding up the data acquisition process. Scanning at coarser 
resolutions can not only make chemical imaging real time but may also lead to higher accuracy 
due to the higher signal to noise ratio of the detector50. Hence, we also collected data at a larger 
pixel size of 25µm x 25µm (at least 16-fold faster) to evaluate the applicability of the procedure 
at lower resolution. As seen from fig. 3(iii) and fig. 4, most classes are identified well, but the 
confidence in data reduces due to larger pixel size. This leads to lower sensitivity which is typical 
of tradeoff between time required to take image and the resolution achieved48. We anticipate that 
a multi-scale scanning algorithm will be practical when translated to use. The tissue could be 
scanned in minutes at low resolution and specific areas can be scanned at higher resolution for 
better accuracy. It is notable that the molecular basis of our histologic approach provides this 
flexibility, and is truly unique to this technology as we have deployed.  In contrast, morphologic 
analysis of conventional stained tissue is specific to the resolution and is very unlikely to yield 
similar results.  The ability to identify areas of concern with coarse resolution and hone into those 
areas with high resolution maybe analogous to scanning at low power and then searching the 
involved areas with high power microscopy. However, the FT-IR imaging based approach is 
significantly quicker and may be automated quite easily. Presence of lymphocytes in 
endocardium as well as in nearby myocardium can be checked by looking up neighbors of pixels 
using simple algorithms; which could also enable us to quantitate foci of infiltrations used for 
grading rejection. Future efforts can be undertaken to incorporate these ideas and making IR 
based detection a practical technique by using focal plane array (FPA) detectors for high spatial 
resolution at faster time frames by utilizing  noise reduction51 techniques.  
                       
Infrared imaging to identify chemical changes in tissue 
According to the ISHLT criteria4, for the sample to be qualified as grade zero (no rejection), there 
should be no evidence of mononuclear inflammation or myocyte damage. We observed that in 
all grade 0 cases, there were negligible lymphocyte pixels, and even the lymphocytes that were 
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found were not encroaching in the myocardium. Thus, using IR spectroscopy, it is very 
straightforward to differentiate between positive (rejected) and negative (not rejected) samples. 
In addition to histologic identification, biochemical changes undergone by tissues can also be 
captured using chemical imaging. Since our hypothesis was that the classifier could capture 
important tissue changes efficiently, we have related specific infrared absorption patterns that we 
identified from the classifier with previous observations. During fibrosis, ECM components 
(majorly collagen) are accumulated in the myocardium52 which is apparent by higher infrared 
absorption intensity of amide III peak in fibrotic regions53. Our classifier correspondingly 
identified the absorbance at 1236 cm-1 (high contribution from collagen15,45,49,54 as an important  
parameter(Table 3 and table 4). Peak due to absorbance at 1236 cm-1 / 1239 cm-1 is due to the 
CH2 wagging vibrations associated with proteins and is known as amide III peak. However, for 
the sample being analyzed here, owing to empirical evidences (Fig 2(i)) and observations from 
past literature discussed above, it can be inferred that major contribution to this peak is coming 
from collagen. With peaks at 1204 cm-1 and 1239 cm-1 reflecting the characteristic vibrational 
modes of collagen proteins-amide III55  (fig. 2 (i)), a significantly low level was observed in 
healthy myocardium. Absorbance (1027 cm-1 to 1032 cm-1) associated with glycogen[56] was 
decreased at sites of fibrosis (fig. 2 (iii)) as previously noted57. Hence, this multivariate approach, 
utilizing multiple biochemical characteristics of tissues, is effective in identifying multiple 
pathologic conditions.  
Together, these results indicate that both the spatial and chemical information can be utilized to 
identify tissue changes during immune response to the allograft. While we use cardiac allograft 
rejection as a proof of concept, chemical imaging can be expanded to identify additional cardiac 
pathologic conditions. Studies show that the false negative rate in identification of myocarditis 
can be up to 45% due to errors in sampling and sensitivity58. Differentiation of lymphocytes from 
other normal constituents like mast cells, fibroblast nuclei, pericytes and endothelial cells is 
difficult via visual pathological examination59. It has already been shown that IR spectroscopy 
can identify different cell types16,60,61. However, it has been very difficult to classify lymphocytes 
using earlier supervised classifiers due to low density of lymphocytes in other tissues, and their 
small size, resulting in problems of mixed pixels at current spatial resolution. It is possible to 
quantify lymphocyte infiltration in tissue in terms of number of pixels per sample. Supplementary 
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table 1 shows the number of pixels marked for each class using gold standard. About 83% of 
these were correctly identified as lymphocytes by our classifier. This data can be combined with 
quantification of associated myocyte damage in order to computationally assess the grade of 
rejection. We are confident that using high definition IR imaging systems62,63 would enable us to 
differentiate between even more cell types, making this technique very useful for pathology 
applications in a variety of conditions.  
While manual examination would require presence of lymphocytes in the section (resulting in 
error due to sampling as well as need to sample multiple times from patient), infrared 
spectroscopy can potentially detect changes undergone by the tissue which are indicative of 
transplant rejection even when lymphocytes are not picked in sampling, reducing the error rates, 
false negatives and avoiding significant trauma to the patient tissue. Apart from chemical 
information associated with tissues, tissues digitally stained with IR imaging approach are 
capable of providing a much better contrast and easy quantification of lymphocytes which can 
greatly reduce the time and effort spent per section by the pathologist.  
This report stresses the capabilities of this approach in a complex condition such as cardiac 
transplant rejection, which traditionally needs careful tissue preparation, multiple stains and 
review by experienced cardiac pathologists to provide accurate diagnoses. Combined with the 
speed of the data acquisition and emerging technologies for high speed IR microscopy42,43, we 
believe this study opens the path to more rapid tissue assessment much closer to the patient than 
previously possible. Eventually, intra-operative and in vivo imaging can be attempted based on 
chemical molecular imaging. This can be made possible by touch probe based fiber optic 
technology on which work is currently under progress. Multiple studies show that spectral in-
vivo analysis is promising using probe based instruments and have previously been applied to 
study atherosclerosis 64-66 and to detect cancer67-68. Using attenuated total reflectance (ATR) 
infrared imaging, mid-infrared light can be used to detect the ailment. Moreover, since this study 
has already identified specific molecular peaks that can be used for detection, we can now build 
instruments that operate on discrete frequencies to give even faster detection systems. This is 
different from near-infrared imaging, which has many pitfalls in making accurate diagnoses69.  
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Although the present study has shown excellent promise in terms of on-site detection, we are 
currently limited by spatial resolution and speed of data acquisition and processing. Spatial 
resolution used in this study can identify single lymphocytes larger than 10 µm, and lymphocytes 
smaller than this can be identified in large enough cluster. While the current study can 
successfully identify grade 0 through grade 4, in order to accurately identify grade 2(mild 
rejection), one would require much better spatial resolution to identify single lymphocytes. This 
task can be accomplished in near future using high definition imaging systems which have spatial 
resolution of the order of single micron, reducing the problem of boundary pixels and enabling 
us to identify every cell more accurately in tissue. Another challenge faced by pathologists is to 
identify whether the rejection is cellular or antibody mediated. Good spatial resolution is 
necessary to identify individual cells and to classify cells that are present in low density in tissues, 
for example macrophages, basophils; or bacterial cells in case of pathogen infections. As the 
project expands, we hope to be able to identify many other cell populations in the region such as 
activated mononuclear cells and pathogens; making spectroscopic analysis of specific cells 
possible. This could in turn enable us to understand other pathological mechanisms of disease 
development. While we were limited by speed in terms of imaging and data processing in this 
study, progress is now being made to reduce data acquisition time by manifolds using discrete 
infrared spectroscopy42,43. The trade-off between the resolution and time can also be improved 
by the use of FPA detectors, using which large areas can be measured at higher resolutions at 
faster time frames, and which are becoming more and more amenable. These advances further 
go on to show that IR imaging provides a potential approach for next generation histology 
procedures that are highly precise and accurate while the automation can lead to better decision 
making closer to the patient. This could be done within a very short period of time; thereby 
reducing the work load on pathologist and bringing smart detection devices to surgery suites. 
 
Conclusion 
The chemical molecular imaging approach offers numerous advantages over traditional sample 
examination techniques, providing a new avenue for clinical diagnosis. Chemical information, 
along with morphologic and architectural tissue information provides for a comprehensive 
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analysis of tissue. Computer algorithms allow us to dispense with staining and pathological 
recognition is aided by color coded images. In this study, we have shown an example of how 
chemical imaging can be applied in cardiac tissues to achieve automated pathology while 
providing a high probability of detection and low probability of false alarm. We identified 
specific spectral characteristics which related to the biochemical changes undergone by the tissue 
which could be used for chemical detection of rejection. In future, we can make this even more 
extensive by differentiating between acute cellular rejection and Quilty lesions. This is the first 
study to show that the chemical molecular imaging approach can be used to diagnose complex 
cardiac conditions, with results equivalent to and probably superior to conventional pathology.  
This technique would also be useful in identifying other cell populations that can be present in 
cardiovascular environment such as activated immune cells, antibody mediated rejection and 
bacterial infections to name a few. It is also possible to integrate this digital data with patient 
history to provide an even more nuanced scientific assessment of disease and prognosis. The idea 
here is to kick start the development of an approach which can give an all-encompassing rapid 
diagnosis at the site of collection of sample without stains and more importantly, assist during 
surgery for identification of diseased and problem areas in the heart & vasculature.   
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Figures and Tables 
 
 
Figure 1: Baseline corrected absorption spectra, normalized using the Amide I peak, for all 
five classes of cells observed in the study. Important spectral differences observed over the 
fingerprint spectral region (1500-900 cm-1) are highlighted in grey and zoomed in without 
offset. 
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Figure 2: Relative intensities of peak height ratios useful in discriminating classes; 
examples from metric definitions (i) 1239cm-1 to 1652cm-1; (ii) 1204cm-1 to 1236cm-1; (iii) 
1027cm-1 to 1543cm-1 
  
Figure 3:  Receiver operating characteristic (ROC) curves demonstrating the accuracy of 
the classification algorithm (i) Training set at 6.25 µm x 6.25 µm pixel size; (ii) Validation 
set at 6.25 µm x 6.25 µm pixel size; (iii) Validation set at 25 µm x 25 µm pixel size 
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Table 1: Confusion matrix for classification for validation data and training data (in 
parentheses) 
 
  Ground Truth(Percentage) 
Class    Endocardium Myocardium Lymphocyte 
Fibrosis 
myocardium 
Fibrosis 
endocardium 
Unclassified 
3.10 2.25 1.68 1.87 2.21 
(10.90) (4.80) (0.90) (0.30) (0.10) 
Endocardium 
12.74 0.08 0.00 1.28 0.55 
(12.30) (0.20) (0.00) (0.30) (0.80) 
Myocardium 
6.42 95.91 0.03 10.11 0.02 
(18.90) (94.50) (0.50) (0.40) (0.00) 
Lymphocyte 
0.19 0.02 82.82 4.74 0.00 
(0.40) (0.00) (85.70) (13.20) (0.00) 
Fibrosis 
myocardium 
52.91 1.54 15.48 81.49 3.53 
(48.50) (0.50) (12.90) (84.80) (19.10) 
Fibrosis 
endocardium 
24.65 0.20 0.00 0.49 93.69 
(9.10) (0.00) (0.00) (1.10) (80.00) 
Total 100 100 100 100 100 
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Figure 4:  Biopsy section array of 16 samples used for validation. Top panel: (i) H&E 
stained image of sections (scale bar represents 500µm); Asterisk marked samples showed 
no rejection in pathologist review. (ii) absorbance at 1236 cm-1 demonstrating differences 
between samples and different cell types; (iii) Classified IR image showing color coded 
pixels indicating different pathological classes; Bottom panel: Magnified view of one 
sample from validation set with matched lower spatial resolution IR image. (iv) H&E 
stained image of section; (v) Classified 6.25 µm x 6.25 µm pixel size IR image; (vi) 
Classified 25 µm x 25 µm pixel image. 
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Table 2: Probability of detection at 10% probability of false alarm 
  Training 
Validation 6.25 
µm 
Validation 25µm 
Lymphocyte 99.1 98.3 72.9 
Fibrosis 
endocardium 
99.9 95.7 93.3 
Fibrosis 
myocardium 
99.7 95.9 62 
Endocardium 86 85.8 48.4 
Myocardium 95.2 97.5 88.7 
Table 3: List of metric definitions found useful to differentiate classes- peak height ratio; 
all values are in wavenumber (cm-1) 
Peak Height Ratio Peak Height Ratio Peak Height Ratio 
Peak 1                   Peak 2              Peak 1            Peak 2            Peak 1           Peak 2            
1389 1236 3315 1236 1204 1236 
1027 1065 1163 1236 1239 1652 
1239 1543 1163 1065 1236 1543 
1389 1452 1452 1543 1236 3300 
1239 3300 1389 1652 1389 3300 
1389 1065 1452 1236 1027 1543 
1405 1236 1155 1452 1032 1236 
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Table 4: List of metric definitions found useful to differentiate classes- peak area to height 
ratio and center of gravity; all values are in wavenumber (cm-1) 
 
            
Figure 5: IR peak assignments for tissue 
Peak area to peak height ratio Center of gravity  
Left area 
bound  
Right area 
bound   
Peak 
position  
Left 
bound  
Right bound  CG 1       CG 2       
1482 1594 1652 1184 1302 1188 1216 
1424 1480 1546 1482 1726 1482 1594 
1184 1300 1652 984 1144 1016 1048 
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Figure 6: Computationally stained infrared image compared with H&E image at various 
grades of rejection. Arrows show lymphocytic infiltration. Top panel: No rejection; 
Middle panel: Mild rejection; Bottom panel: Moderate rejection.  
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 Table 5:  Number of pixels for each class in training and validation sets 
 
 
 
 
  Training Validation 
Myocardium 218024 229001 
Endocardium 3508 4317 
Lymohocyte 18671 3219 
Fibrosis 
Myocardium 11904 18158 
Fibrosis 
Endocardium 77287 51848 
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CHAPTER 2 
Translation of Infrared Chemical Imaging for Cardiovascular Evaluation2 
 
Abstract 
Infrared (IR) spectroscopic imaging has been applied to study histology of cardiovascular tissue, 
primarily using Fourier transform IR (FTIR) Imaging. Here we describe results for histologic 
imaging of cardiac biopsies using a fast, discrete frequency IR (DFIR) imaging system. 
Histologic classification of tissue is understood in terms of the constituent frequencies and 
speeded up by careful optimization of the data acquired. Results are compared to FTIR imaging 
in terms of the signal to noise ratio and information content. 
 
Introduction 
Measuring local tissue morphology as well as expression of biochemical components such as 
collagen, glycogen, glycolipids is important for understanding and evaluating cardiovascular 
diseases. The typical assessment today focuses on assessing morphology and typically involves 
histological analysis and immunostaining that often provide qualitative data while requiring 
expensive reagents, time and effort of pathologist to determine the disease. Biochemical assays 
for molecular analyses of tissue are more quantitative in nature are but are usually destructive, 
often provide average values and do not allow for later use of tissue for other tests. Infrared 
spectrochemical imaging is a non-destructive tissue analysis method that can provide both 
qualitative and quantitative information, in an imaging format, about both the morphology and 
several biologically-important chemicals present. A major focus for IR imaging has been for 
developing protocols to analyze tissue.1–6 Recent results have advanced the capabilities of IR 
                                                          
2 Reprinted, with permission, from Saumya Tiwari, Jai Raman, Vijaya Reddy, Miranda Dawson, and Rohit Bhargava. "Translation of infrared 
chemical imaging for cardiovascular evaluation." In SPIE BiOS, pp. 97040X-97040X. International Society for Optics and Photonics, 
2016. doi:10.1117/12.2230004 
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microscopes7–9, computing10 and theoretical understanding11 as well as provided a number of 
interesting advances in high-definition spectral12,13 and spectral-spatial methods14,15 for tissue 
histology, cellular analysis16–18, diagnosis of disease19, obtaining prognostic information20,21 and 
providing new visualizations for digital molecular pathology22. More recently, this technology 
has also garnered interest for identification of cardiovascular disorders23–28.  
In particular, previous studies using FTIR spectroscopy have identified bands with significant 
collagen contribution in order to study its distribution and remodeling  in the cardiac tissue29,30. 
Rabee et al showed the correlation of band at 1338 cm-1 with immunohistochemical stain for 
collagen type I and trichrome stain31. This is important in identifying fibrosis32,28, myocardial 
infarction24,33, and specific type of collagen degradation can be related to cartilage 
degeneration34.  Studying heart tissue can also give information about other diseases in body. For 
example, glycogen and glycolipid content is related to diabetes-related changes in heart35 and 
chronic kidney disease can lead to accumulation of lipid in the cardiac tissue36. To study these 
diverse and varied effects, it is pertinent to not only develop infrared chemical imaging based 
detection models for heart tissue, but to also optimize speed of acquisition with data quality to 
enable extension of chemical imaging to other associated conditions. A major recent advance 
that promises high speed data acquisition and high-fidelity imaging lies in the development of 
IR spectral microscopes that employ quantum cascade lasers (QCL) as sources.37–44 While 
several reports of these instruments exist, they haven’t been used extensively for digital 
pathology yet and the area represents considerable potential for developing new protocols for 
clinical use. In this study, we discuss the translation of IR imaging for cardiovascular disease 
diagnostics using a discrete frequency IR (DFIR) instrument based on QCLs. In particular, we 
focus on demonstrating how a small number of spectral features45 can rapidly provide 
diagnostically useful information.  
 
Methods 
Formalin-fixed, paraffin-embedded tissues were obtained from the archives of the department of 
Pathology, Rush University Medical center, Chicago. Samples were imaged using and FTIR 
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imaging spectrometer (Perkin Elmer Spotlight) and truncated to a range 748 cm-1 – 4000 cm-1 at 
spectral resolution of 8 cm-1 with step size of 4 cm-1 and square pixel size of 6.25 μm on each 
side. DFIR data was collected using Agilent Hyperscan system in the range 930 cm-1 to 1746 cm-
1 using step size of 6 cm-1 and square pixel size of 5 μm on a side. ENVI IDL 4.8 (Environment 
for Visualizing Images with Interactive Data Language) software was used to process the image 
files.  In order to eliminate non-cellular regions of the tissue sample, a mask was created that 
only selected a threshold of absorbance values at the amide I peak (1652 cm-1).  Specific regions 
of interest were applied to the same areas on both the DFIR and FTIR images.  The average 
spectrum was then obtained at each of these regions.  Resultant data was baseline corrected and 
normalized to the amide peak (1652 cm-1).  For unsupervised classification, iso data classification 
was used in ENVI IDL. Minimum number of classes was set at 4 while maximum number of 
classes was set at 5. A maximum of 3 iterations were performed with a change threshold of 10% 
with the condition that the classification would end before the set number of iterations if the 
number of pixels in each class changed by less than the threshold. In case of FTIR data, only 
spectral range of 900cm-1 to 1800cm-1 was used for classification.  Finally, the relative intensities 
of collagen and glycogen were calculated with band math. Baseline corrected Amide III (1236 
cm-1) and glycogen (1032 cm-1) absorbance values were divided by the values at the referential 
amide peak (1652 cm-1). The resulting ratios were plotted in the form of color intensity map.  
 
Results 
Absorption spectra collected from same areas (normal myocardium) of two different samples 
collected on the FTIR instrument and DFIR system were compared, as shown in figure 1. The 
signal to noise ratio (SNR) obtained in case of hyperspectral scans of DFIR instrument was lower 
than the SNR obtained on FTIR instrument, while the peaks and peak widths in spectra were 
similar from both the instruments with some differences in the absorbance values. These 
differences are to be expected in terms of the different optics of the instrument and for different 
shapes within local sample morphology46 and are relatively minor for most cases. We have also 
shown plotting of discrete frequencies with extrapolation for the same set of samples to 
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demonstrate the utilization of discrete frequency data to reproduce peaks of interest using a 
limited set of measurements, reducing scan time by manifolds.  
An unsupervised Iso Data Classification algorithm was used to identify different classes present 
in the tissue. With the prior information that the sample had Myocardium, Fibrosis, Necrosis and 
non-tissue pixels, the minimum number of classes was set at 4. Myocardium regions, colored 
yellow in classified images, correlated with the Hematoxylin and Eosin (H&E) stain in both FTIR 
and DFIR data (Fig 2). Fibrosis and necrosis could not be differentiated from each other in terms 
of class label (green and blue colors). This was confirmed by plotting average spectra of the 
regions identified as Myocardium against other two classes (combined as “other”). In both the 
samples (Fig 3), regions other than myocardium showed higher intensity of normalized Amide 
III peak, indicating that these two classes had stronger contribution of collagen as compared to 
myocardium labelled class. This shows that both the data sets performed similar to each other in 
an unsupervised classification system. The extent of agreement in classification was not 100% 
and remains to be probed further.  
While unsupervised classification gave a preliminary indication of applicability of DFIR data for 
identification of cell types, we further sought to examine if it could correlate with pathologist’s 
observation of fibrosis, ischemia and amyloid deposition. Towards this end, we plotted the 
relative band intensities of the Amide III and the glycogen-specific features which contributed at 
band 1032cm-1 with Amide I band (Fig 4). As expected, collagen expression, which is a major 
contributor to Amide III correlated highly with pathologist identified regions of fibrosis as noted 
in our earlier studies47. We expected to see variations in levels of glycogen for samples with 
ischemia, but notable differences were not found in these samples compared to control healthy 
samples. This could be possibly due to glycogen washing out during sample preparation steps, 
but further studies would be needed to provide a definitive answer.  Interestingly, peak height 
ratio of 1032cm-1 band with Amide I band appeared significantly high in samples reported to 
have amyloid deposition (Fig 4, last panel). This is an exciting discovery since it is very difficult 
to distinguish between amyloid depositions and fibrosis through H&E stains alone. As expected, 
this could not be differentiated directly via the Amide III band intensity color map since both 
collagen and amyloid deposits contribute overlapping vibrational modes within the band. 
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Introduction of DFIR systems to routine lab use and data analysis towards pathology has shown 
very promising outcomes. Our results indicate that not only can DFIR data be applied in a similar 
manner as FTIR data towards digital pathology, it also has potential to enable pathologists 
identify regions that are visibly similar but biochemically different in their traditional staining 
methods. The findings reported here are on a small data set and would need further validation on 
larger data sets. A detailed protocol will need to be constructed and statistical validation 
understood in light of various other factors48 before attempts at clinical translation. At present, 
this works demonstrated the potential of DFIR imaging and its excellent capacity towards digital 
pathology for cardiovascular diseases.   
 
Conclusion 
In this paper, we describe the application of a DFIR imaging system for the analysis of 
cardiovascular biopsy samples. Although much work needs to be done in order to make the SNR 
comparable to conventional FTIR imaging systems and the development of a clinically 
translatable protocol, it can be seen that the technology performs well in identification of many 
biochemical signals. This approach can be a nice complement to other emerging approaches for 
intraoperative aseessment34.  
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Figures  
 
Figure 7: Absorption spectra of two cardiac biopsy samples collected on Fourier transform 
infrared (FTIR) spectroscopic imaging and quantum cascade laser (QCL)-based discrete 
frequency instrument. 
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Figure 8: Iso Data unsupervised classification on FTIR ((i) and (iv)) and DFIR ((ii) and (v)) 
data. Scale bar on H&E image indicates 6 mm.  
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Figure 9: Spectral comparison of classes obtained using unsupervised classification. Data 
shown is from FTIR instrument corresponding to classes identified in figure 2. 
60 
 
  
 
Figure 10: Absorbance of Amide III at 1236cm-1 (top) and Glycogen  at 1032 cm-1 (middle) 
normalized by ratio with Amide I peak obtained from DFIR imaging data show good 
correspondence with macroscopic structure seen in conventional H&E stained histologic 
images (bottom). 
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CHAPTER 3 
Towards Translation of Discrete Frequency Infrared Imaging for Rapid Digital 
Histopathology of Clinical Biopsy Samples3 
 
Abstract 
Fourier transform infrared (FT-IR) spectroscopic imaging has been widely tested as a tool for 
stainless digital histology of biomedical specimens, including for identification of infiltration and 
fibrosis in endomyocardial biopsy samples to assess transplant rejection. A major barrier in 
clinical translation has been the slow speed of imaging. To address this need, we tested and 
report here the viability of using high speed discrete frequency infrared (DFIR) imaging to obtain 
stain-free biochemical imaging in cardiovascular samples collected from patients. Images 
obtained by this method were classified with high accuracy by a Bayesian classification 
algorithm trained on FT-IR imaging data as well as on DFIR data.  A single spectral feature 
correlated with instances of fibrosis, as identified by the pathologist, highlighting the advantage 
of the DFIR imaging approach for rapid detection. The speed of digital pathologic recognition 
was at least 16 times faster than the fastest FT-IR imaging instrument. These results indicate that 
a fast, on-site identification of fibrosis using IR imaging has potential for real time assistance 
during surgeries. Further, the work describes development and applications of supervised 
classifiers on DFIR imaging data, comparing classifiers developed on FT-IR and DFIR imaging 
modalities and identifying specific spectral features for accurate identification of fibrosis. This 
addresses a topic of much debate on the use of training data and cross-modality validity of IR 
measurements. Together, the work is a step towards addressing a clinical diagnostic need at 
acquisition time scales that make IR imaging technology practical for medical use.  
 Introduction 
                                                          
3 Reprinted, with permission, from Saumya Tiwari, Jai Raman, Vijaya Reddy, Andrew Ghetler, Richard P Tella, Yang Han, Christopher R 
Moon, Charles D Hoke, Rohit Bhargava. “Towards Translation of Discrete Frequency Infrared Spectroscopic Imaging for Digital 
Histopathology of Clinical Biopsy Samples.” Analytical Chemistry 88.20 (2016): 10183-10190. doi: 10.1021/acs.analchem.6b02754 
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Cardiovascular diseases (CVDs) are the leading cause of mortality in the United States, 
accounting for one in seven deaths1. Histopathological examination is often the final arbiter in 
making diagnoses and guiding therapy for a variety of CVDs, largely relying on manual 
examination of microscopic structures in tissue that become apparent only by the application of 
exogenous contrast agents such as dyes and fluorescent probes. As opposed to cancer pathology, 
in which gross tissue changes allow a simple recognition of disease in most cases, tissue changes 
are more subtle in CVDs and require careful human examination. Due to the need for tissue 
processing and staining followed by manual examination, the recognition process cannot be real-
time. Consequently, there remains a large temporal gap between histopathological analyses in 
the laboratory and the need for input in the surgical suite. A number of stainless staining and 
diagnosis approaches have been suggested to visualize tissue structure2, including those focused 
on CVDs3. While these technologies have shown promise in performing histologic analyses, the 
data acquisition has been slow and incapable of addressing the time gap to bring real-time 
pathology to the site of intervention where it can have the most impact.  
Fourier transform infrared (FT-IR) spectroscopic imaging has shown great promise in cellular 
recognition4–8, metabolic analysis9,10, disease diagnoses11,12 and prognosis13,14. In FT-IR 
imaging, approximately 2000 spectral elements are typically acquired per pixel in the image. 
Using a metrics based approach15,16, it has long been demonstrated that not all recorded data 
may be needed for accurate histologic recognition. By using Bayesian classification, for example, 
a subset of data can be identified that gives accurate classification15 using 10-50 metrics for 
many different types of tissues15. Hence, the potential exists to decrease time for providing 
histologic images from a sample simply by acquiring only the needed data and increasing 
analysis speed ~20-100-fold. This concept, however, has not been previously realized. With the 
development of discrete frequency IR imaging instruments17,18 single band images can be 
generated within seconds for areas of the order of cm2 and pixel size of the order of microns. 
While initial attempts using filters19 did not provide high signal to noise ratio (SNR) for practical 
use, quantum cascade laser (QCL)-based microscopes20–23 have dramatically improved and 
shown promise for tissue imaging24,25. In a previous study, we used unsupervised clustering to 
differentiate between biochemically different regions in cardiac biopsy samples26. Recently, a 
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two class classifier was used to differentiate between cancerous and normal epithelium using 
DFIR imaging25. Since the technology is relatively new, a number of issues remain to be 
resolved. First, it is not clear whether spectral features for DFIR imaging should or can be 
selected from FT-IR imaging data, which provides access to all the possible spectral features and 
high SNR. Or alternately, it is not known whether classification should be developed de novo 
using DF data that suffers from low SNR but would remove imaging modality dependent effects. 
Second, the advantage of the DF approach is not apparent. In order to utilize the speed advantage 
of the system, an ideal case scenario would be a single spectral feature to differentiate between 
the classes but it is unclear whether the SNR of the data are sufficient to permit such a 
determination. Finally, multiclass classifiers have not been developed on DFIR imaging data. 
This raises questions about the possibility and accuracy in identifying multiple classes with DF 
technology. In this study, we focus on these extant issues. Specifically, we demonstrate the 
application of DFIR imaging for automated pathology of CVDs by analyzing the performance of 
different two-class and multiclass classifiers and its potential for clinical implementation. 
Optimizing recognition, we also show that a single spectral feature was sufficient to differentiate 
between two histopathological classes, namely myocardium and fibrosis, giving tremendous 
advantage in terms of speed of detection. Finally, we sought to demonstrate rapid digital 
pathology for use in evaluating cardiac tissue, since intra-operative recognition can be 
advantageous in real-time.  
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Methods: 
Sample acquisition 
 Fourteen patient samples were collected in collaboration with Rush University Medical Center. 
All sections provided were anonymized and no patient identifying information was recorded for 
the experiments. The samples were formalin fixed, paraffin embedded and microtomed onto low 
E glass slides (Kevley Technologies) at 5μm slice thickness for infrared imaging. 
Deparaffinization was performed by repeated hexane washes for 24 hours before imaging. No 
further processing was required for the samples for IR imaging. A serial section was acquired on 
a glass slide for each sample to perform Hematoxylin and Eosin (H&E) stain. An expert 
pathologist identified histologically relevant regions in the biopsies. Based on this, 10 patient 
samples were identified to have histologically normal myocardium regions and seven samples 
contained regions identified as fibrosis. In addition, previously collected thirty-five anonymized 
patient samples’ FT-IR imaging data were used to develop the FT-IR imaging data-based 
classifiers.  
Data acquisition and processing  
FT-IR imaging data were acquired using a 4 cm-1 spectral resolution, a 6.25 micron pixel size 
and one scan per pixel following sample preparation and image collection protocols described 
earlier27–29.  For each image, a background was collected using identical spectral and spatial 
parameters with 120 spectral co-additions. DFIR data was acquired on Agilent LaserDirect IR 
imaging system using a reflection-absorption sampling geometry. The instrument settings 
allowed data collection at 1, 3, 5 and 10 m pixel sizes and pixel size of 5 m was chosen for 
imaging. When acquiring spectra, a step size of 6 cm-1 was used to step the discrete frequencies 
of the quantum cascade laser source.  DFIR data were imported using MATLAB and further 
processing was performed in Environment for Visualization (ENVI) - Interactive Data Language 
(IDL) version 4.8. Programs for Bayesian classification were developed in-house and 
implemented in ENVI. The data collected in the form of tiles was mosaicked in ENVI-IDL using 
in house written algorithms. Tissue pixels were selected by creating a mask at threshold value of 
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0.2 of peak height at 1652 cm-1 after a linear baseline correction using absorbance values at 1482 
cm-1 and 1710 cm-1.  
Development of FT-IR classifier 
In a previous study, we had developed a Bayesian classifier to identify myocardium, fibrosis and 
lymphocytic infiltration3 following earlier protocols15,29. Briefly, the data was converted into 
quantitative ratios of spectral features or characteristics of individual bands called metrics. This 
was done by specifying 148 spectral features which corresponded to peak height ratios, peak area 
to height ratios, peak area to area ratios and centroid position of peaks for every pixel. The ground 
truth was specified by marking regions of interest (ROI) on IR images corresponding to 
pathologist annotated regions on the H&E image from a serial section. These metrics and 
associated ground truth marked pixels were used to train the classifier. We did not use the 
previously built FT-IR imaging data based Bayesian classifier as-is since the range of the DF 
instrument is 800 cm-1 to 1900 cm-1, whereas the original FT-IR imaging data based classifier 
utilized the range of 750 cm-1 to 4000 cm-1. A new Bayesian classifier was developed using the 
truncated FT-IR imaging data and validated on independent set of FT-IR imaging data before 
applying it to DF-IR imaging data. Receiver Operating Characteristic (ROC) curves were 
calculated for FT-IR imaging data training and validation sets. All images acquired in DF-IR 
imaging mode were classified with this classifier and ROC curves, confusion matrix and overall 
accuracy were calculated for DF-IR images with previously established ground truth in ENVI-
IDL.  
Development of DF-IR classifier 
Data preprocessing was performed as described in section 2.2. Data to metric conversion was 
performed by defining 185 metrics in the DFIR data based on spectral variations observed in the 
data. In order to develop Bayesian classifier, the DF-IR data was split into training and validation 
set. Seven samples were used for training the classifier. In case of multi-class classifier, for each 
of the training and validation sets, at least three patient samples were marked with myocardium, 
fibrosis and blood class. One additional ‘cell death’ class was added through one sample in 
training and two samples in validation. Ground truth was marked on this data using pathologist 
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annotated H&E images. Only the regions with high confidence in identifying histological classes 
were marked. Bayesian classifier was developed on this data set using previously developed 
protocols. ROC curves were calculated for both training and validation datasets. Confusion 
matrix and overall accuracy was calculated on classified image acquired from validation set. 
Both confusion matrix and ROC curves were calculated in ENVI IDL prebuilt toolbox for post-
classification processing.  
Specific band based detection 
 Spectral features which led to correct classification in the classifier models were considered 
individually to identify features that offered high overall accuracy of distinguishing between 
myocardium and fibrosis. In order to distinguish between the classes, a threshold was used to 
separate the two classes from each other. Multiple thresholds were tested on each band 
individually for overall accuracy in separation of classes and the spectral feature with highest 
overall accuracy was chosen. Class images were created at the threshold which produced highest 
accuracy and confusion matrix was calculated using the previously established ground truth.  
Results and Discussion 
Data collection and analysis on DFIR imaging instrument 
We imaged identical areas of two patient samples using both FT-IR and DFIR systems to 
compare the spatial and spectral features of data acquired using the two different modalities. 
Images of the Amide I absorbance were used to compare spatial quality and fidelity. No other 
corrections were performed on the images (figure 1 (A, B, E, F)). Comparing spectra obtained 
from FT-IR and DFIR systems using the same area in tissue and background, it can be observed 
that the raw spectra averaged over >5000 pixels have similar spectral characteristics in terms of 
peak positions (figure 1 (C, G)). While averaging provided similar quality spectra, point-by-point 
comparisons of spectra showed some differences likely arising from differences in optical 
configuration30 and noise. In addition to small differences in absorption, DFIR spectra had lower 
SNR (figure 1 (D, H)). As opposed to FT-IR imaging data that have uniform noise across the 
spectrum due to the transformation from the retardation to the spectral domain, the DFIR 
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instrument reflected the underlying fluctuations at specific positions even apparent in single 
beam background spectra. This not only makes the noise non-uniform across the spectrum (figure 
1 (C, G)) but is likely correlated with laser intensity fluctuations as well making, as common for 
shot noise in most lasers, it difficult to signal average.  
A major factor in successful classification is the quality of the data, which typically implies an 
increase in measurement time per pixel or decrease in total area covered, to increase the SNR. 
To determine the speed advantage of DFIR instrument, we first acquired data at the maximum 
rate of approximately 15 seconds per band at 5 µm pixel size, which is the typical cellular size, 
and for a sample area of ~2 mm x 2 mm, which is the typical biopsy size. It is difficult to achieve 
a straightforward comparison of this scan time with an FT-IR imaging system, since the 
techniques are fundamentally different in light utilization, spectral bandwidth and modulation. A 
general comparison of QCL and FT-IR imaging is available18 by normalizing the performance 
of instruments by considering number of pixels imaged, SNR and the time required for image 
collection. A similar examination can be conducted for point microscopy systems with this 
system17, but is not productive. FT-IR point microscopy systems do not typically perform well 
at low aperture settings and need a synchrotron31 for these aperture sizes. A more reasonable 
comparison is between a globar-equipped FT-IR imaging system without apertures and the DFIR 
approach with this bright light source. Each system is playing to its advantages in such a 
comparison, i.e. the light of the large sized globar source is used for widefield imaging while the 
collimated and narrow laser light is used for point microscopy. In this task-based comparison of 
fit for purpose instruments, we proposed that the time required by the DFIR imaging approach 
be compared to the FT-IR imaging approach to obtain a spectral classification. We focused on 
getting the highest possible SNR that could be obtained from the DFIR instrument. In figure 2, 
the effects of signal averaging are demonstrated for low and high speed settings, which 
corresponded to a higher and lower detector integration time respectively. Figure 2(A) compares 
the size of the images at various resolution settings, showing no appreciable change in features. 
The SNR did not change significantly by changing speed as seen from the spectral profile of 5 x 
5 block of pixels in figure 2(B). This is understandable since, as opposed to FT-IR imaging 
systems, the SNR is dominated by laser fluctuations and not by detector noise. Since our goal 
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was to reduce the imaging time, high speed settings were used henceforth. Next, we compared 
the time required to collect images at different pixel sizes for the full range provided by the 
instrument (figure 2(C)) for an area of 2.5 mm2. For comparison, the same area was imaged 
using an FT-IR imaging system with typical parameters for spatial and spectral resolution. A 
comparable spectral range could be obtained by using an undersampling ratio to reduce the FT-
IR scan time further by more than a factor of 2. 
For images taken over the full spectral range of the DFIR instrument and pixel sizes of 5-10 μm, 
the system does not offer significant speed advantages compared to the FT-IR approach. The 
higher intensity of the QCL is an advantage but the low noise thermal source, and the efficient 
interferometry process proves remarkably competitive. However, for the acquisition of a small 
number of bands, the time taken by the DFIR system reduces proportionally. Therefore, even 
though the initial research time required for developing classification algorithms would still 
remain comparable to FT-IR imaging systems due to the need for acquiring spectra over the 
entire bandpass, it is only the combination of DFIR acquisition with metrics-based classification 
that can enable rapid diagnoses in routine application to samples. The caveat here is the 
difference in SNR obtained from the two instruments, which is known to affect the classification 
accuracy32. While commercial FT-IR imaging instruments offer a spectral SNR of above 200, 
the DFIR instrument used in this study had at least 5 times lower SNR. Thus, two important 
future improvements are apparent. First, SNR can be improved by improving the hardware and 
image collection protocols. Second, post-acquisition noise reduction techniques need to be 
developed for discrete frequency data32; in order to be not limited by SNR for obtaining high 
classification accuracy. While the former is likely to be a major focus for the field in the coming 
years, the latter offers a solution that can be implemented faster.  
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Classifier training on FT-IR data and application on discrete frequency data 
The underlying assumption in development of spectral Bayesian classification protocols is that 
switching between image collection modalities would not affect the results in identification of 
cell types since inherent biochemical contrast is utilized for chemical staining. To test this 
assumption, we first trained a Bayesian classifier on FT-IR imaging data to identify 
histologically normal myocardium and fibrotic regions. Upon calibrating in 900-1800 cm-1 
range, 13 metrics were identified to provide adequate performance (Supplementary table 1). The 
classifier generated from this data, in the form of probability distribution functions and list of 
metrics to use for classification was applied as-is to DFIR data. ROC curves generated for this 
classifier are shown in figure 3 ((i), (ii) and (iii)); along with the representative classified images 
and their comparison with H&E stained images (figure 4 (A, E, I)). The regions identified by the 
pathologist as fibrosis have been marked with arrow in figure 4 (D, H, L). Correspondingly, 
fibrotic regions can be seen in classified IR image. When a control sample with no fibrosis 
(figure 4 (A)) was classified, we did not observe any bulk fibrosis in the classification. 
Comparing the ROC curves obtained by applying the classifier on FT-IR and DFIR data, it is 
clear that the classifier had lower area under the ROC curve for DF-IR data. The overall 
accuracy of classification was calculated to be 94.42% (Table 1) on the DFIR dataset that was 
also used for validation in section 3.3 in order to remove effect of marking ground truth while 
comparing performance of FT-IR and DFIR classifier. In conclusion, DFIR data could be 
classified with high correspondence to pathologist identified classes using classifier developed 
on FT-IR data, though not perfectly, with overall accuracy in the neighborhood of 95%.   
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Development of classifiers on DFIR data 
In order to understand whether high sensitivity and specificity classifiers can be built on DF data 
due to its noise characteristics, we started with a binary classification model with myocardium 
and fibrosis classes. The training and validation sets were split and classified as described in 
methods. Using the Baysian approach, 11 metrics were identified which contributed in the 
decision making of the classifier (Supplementary table 2). We calculated the ROC curves of 
training and validation data sets (Figure 3 (iv) and (v)) and observed that the area under the curves 
(AUC) of the ROC of classifier trained on DFIR data was lower as compared to the classifier 
trained on FT-IR data. The accuracy was 90.99% (Table 2). Figure 4 (B, F, J) shows a comparison 
of images identified with this classifier with corresponding H&E images in Figure 4 (D, H, L) 
for three different samples. Pinpointing the cause for lower AUC values in DFIR classifier is 
challenging since the dissimilarities in FT-IR and DFIR classifiers can be found at multiple stages 
of data collection and characteristics of the data. Considering the inherent difference in imaging 
modalities, further causes for divergence of the results are likely to occur due to lower SNR 
obtained in DFIR data, differences in pixel size and spectral step size. In terms of future 
application of pre-built classifiers on discrete frequency data, some of the factors outlined above 
such as spectral step size are easily matched to FT-IR data on which the classifier was built. 
Spectral matrices can be modified based on baseline and peak positions and to account for the 
variations in pixel size when data from different modalities needs to be matched but how the 
differences in pixel sizes can impact classification likely depends on the tissue and its 
morphology.  
Specific band based detection for digital detection of fibrosis 
Even though high accuracy classifiers can be developed using DFIR systems, the full potential of 
the system can only be realized when high speed detection can be optimized. In terms of 
identification of various cell types, multivariate analysis is required for disease detection and has 
been applied successfully in past15,33–38. Depending on the biochemistry of the tissue, we 
hypothesized that a single spectral feature (metric) could exist that can give a fast identification 
of disease in some cases. Metrics were analyzed instead of raw data since conversion of data to 
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metric is an effective way to reduce data while preserving spectral features15. In addition, 
baseline correction and normalization was implemented in metrics which is important to remove 
tissue thickness variation related artefacts and IR light dispersion related effects27. Specifically 
in case of heart tissue, we observed that fibrosis, which results from high deposition of 
extracellular matrix could be easily separated from myocardium by observing the contrast 
produced from absorbance at 1236 cm-1 peak3. Additional peaks could be of interest in 
generating contrast as well, and more recently, regions of fibrosis and hepatocyte populations in 
liver were visualized by plotting absorbance at 1656 cm-1 and 1032 cm-1 obtained on a discrete 
frequency imaging instrument39. In the current model, we were interested in identifying a single 
feature to produce contrast indicative of high ECM deposition in cardiac biopsies. We selected 
all 11 spectral features (metrics) that the DF-IR Bayesian classifier utilized for differentiation 
between myocardium and fibrosis. We then set a range of all possible values for each of these 
metrics by plotting the histograms of values from myocardium and fibrosis pixels. Over this 
range, a threshold was needed to determine whether the pixel belonged to myocardium or 
fibrosis based on the value of the metric. Twenty threshold values were tested for each metric 
and accuracy was plotted at each metric to determine the optimal threshold. Based on the 
maximum accuracy obtained (supplementary table 2), the metric corresponding to peak height 
ratio of amide III (1236cm-1) to amide II (1542 cm-1) was identified to be the top performing 
metric. Fine optimization of threshold was performed for this metric to identify the operating 
point of threshold (supplementary figure 1).  The results obtained by this method (figure 4 (C, G, 
K)) can be compared to results obtained from the classifiers and the H&E in figure 4 (D, H, L) 
and the confusion matrix for this detection has been shown in table 3. As expected, the single 
feature based system performs worse than both FT-IR and DFIR classifiers in terms of overall 
accuracy, highlighting the need for multivariate analysis for accurate identification. 
Nevertheless, a single feature comprising of six spectral frequencies achieved an impressive 
87.5% accuracy, which makes it ideal for initial, real time probing of the sample to identify 
tissue scarring before further analysis can be performed. Moreover, in disease states a single 
pixel (equivalent to a single cell) is of little meaning and the diagnosis is made by observing 
characteristic distribution of cells and ECM in a biopsy; which can be accomplished with the 
models developed here. 
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Multiclass detection with DFIR data 
Last, we sought to examine whether multi-class classifiers can be developed with DFIR data. 
Here, to obtain a more comprehensive and useful model, we expanded the approach for general 
cardiac pathology by adding more histological states.   Fibrosis is the scarring of tissue due to 
deposition of excess extra-cellular matrix, which can lead to reduction in functionality of heart 
40,41. Increased fibrosis can lead to loss of contractile function and reserve42. Additionally, 
scarring causes high mechanical stiffness and diastolic dysfunction 43. Cardiac amyloid 
deposition is a pathological feature of advanced cardiomyopathy. Unlike conventional 
amyloidosis, this histopathological feature is due to breakdown products of normal or abnormal 
proteins called amyloids that accumulate in the heart44. These conditions can result in increasing 
heart stiffness and eventual deterioration of heart pumping function44. Thus, identification of 
cell death and protein deposition in cardiac tissue is important and can be indicative of many 
cardiomyopathies. In the newly expanded classifier, we looked for these tissue damage signatures 
in congenital heart. In the limit of the samples studied, the classifier performed robustly to 
identify myocardium, fibrosis, blood and cell death, which combined the classes of apoptosis, 
necrosis and infarction. As expected, multiclass classifier required additional information that 
was evident as the number of metrics needed to perform classification increased to 18 
(supplementary table 3). The area under the curve of the ROC curve appeared to be lower for 
validation set when compared to the training set (figure 3 (vi) and (vii)) and achieved an accuracy 
of about 83% (table 4).  There is potential to further improve classification accuracy by training 
on a larger dataset since patient to patient variations can have greater effects when the classifier 
is trained with small number of samples. As shown in figure 5, additional classes were identified 
by the classifier built and trained on DFIR data and showed correspondence to pathologist 
identified regions of cell death, red blood cells, myocardium and extracellular matrix (ECM). 
The accumulation of fibrous tissue in the ECM corresponded with pathologist identified regions 
of fibrosis. Since amyloid is also characterized by interstitial protein, the ECM signature could 
correspond to collagen as well as other proteins and accurate interpretation is dependent on 
character of the protein, spatial location and distribution. This can be easily performed on 
digitally classified images by employing neighboring pixel analysis towards an advanced 
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automated histology. We also anticipate that high speed identification of multiple histological 
classes can benefit from a multiclass Bayesian classifier developed specifically on DFIR data to 
provide reliable classification in a short time.  
Discussion 
In this study, we built two histologic classifiers that were trained on FT-IR and DFIR data 
respectively. We used a completely independent set of patients for training the FT-IR classifier 
which was not used for DF-IR imaging. Since patient samples used to train FT-IR and DFIR 
classifiers were different, we sought to compare the spectral features selected by each of these 
classifiers (supplementary table 1 and supplementary table 2) and study if similar biochemical 
information was identified in both classifiers. We observed that both classifiers utilized peaks in 
the 1027 cm-1 – 1040 cm-1 which could have contributions from glycogen (C-O and C-C 
stretching motions) and nucleic acids (phosphodiester groups and C-O stretching in ribose or 
deoxyribose). Both classifiers also select peaks around the 1070 cm-1 to 1090 cm-1 region which 
has heavy contribution of symmetric phosphate stretching from nucleic acids and additionally 
some stretching from glycogen C-O and C-C bonds. Therefore, even though the classifiers were 
constructed on two independent set of patients using two different imaging instruments, not only 
did the classifier provide accurate results, but also the peaks that contributed the most to 
differentiation between the two classes were conserved in different metric definition 
combinations. Interestingly, one metric was identical between the two classifiers, corresponding 
to peak height ratio between amide III (1236 cm-1) and amide II peak (1542 cm-1 or 1543 cm-
1) with some overlap with phosphate vibration of nucleic acids. In the tissue studied, high values 
of this ratio were always obtained in fibrotic regions which did not have high cell density, 
implying that collagen and extracellular matrix proteins could be the highest contributors to this 
metric. The conservation of spectral features across classifiers built on different platform 
highlights the importance of Amide III band in tissue distinction and could possibly be the most 
important decision making step in differentiating between myocardium and fibrosis. This was 
confirmed by calculating accuracy for each of the DFIR classifier metrics towards differentiation 
of myocardium and fibrosis (supplementary table 2). To maximize the advantage of speed in 
DFIR, we confirmed that plotting a single metric of normalized Amide III absorbance at 1236 
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cm-1 correlated with fibrotic regions, enabling an even faster fibrosis identification protocol. The 
fibrosis regions identified in this manner matched with fibrosis regions recognized by the 
classifier. Referencing to figure 2, using six spectral bands for identification of fibrosis would be 
significantly faster than conventional FT-IR imaging system to obtain contrast produced in figure 
4 (C, G, K). Multiclass classifier could be developed with high accuracy for classification of 
many other classes and utilized only a fraction of full range of frequencies. Such an approach has 
a potential to be further improved by adding more classes with the developments in 
instrumentation to improve SNR and using more number of samples for building a robust 
classification system. The aim of this paper was to introduce direct application of new generation 
IR based imaging and staining technology towards digital pathology. To that end, we have 
omitted detailed discussion about the instrumentation in terms of spatial and spectral noise and 
SNR which are ongoing. These will be addressed in details in future work.  
Conclusions 
This study demonstrates a DFIR imaging approach for rapid identification of complex 
histopathological states in the heart and, in particular, the rapid identification of tissue scarring. 
Classification was achieved by using a limited set of frequencies; this reduction in data acquired 
was the factor responsible for the speed advantage. We observed that the classifier developed on 
FT-IR imaging data performed with high accuracy on DFIR imaging data. This is significant 
since this may enable us to apply previously built FT-IR imaging data based classifiers on DFIR 
imaging data at high speeds by identifying specific spectral features of importance. In addition, 
it offers a way to get high accuracy in digital histopathology using DFIR data. Despite low SNR 
data currently recorded with the DFIR system, the DFIR imaging data based classifier could also 
identify tissue types correctly with high accuracy. While this dataset is not comprehensive for all 
cardiomyopathies, further work could ensure high accuracy and expansion of classifier. There is 
also significant potential for faster triaging of samples. Fast identification using IR spectroscopic 
imaging is becoming a reality with new imaging instruments and the DFIR approach, which 
could permit real-time visualization of some information with specific regions being probed in 
greater spectral detail. Further, the same setup can lead to imaging at different pixel sizes. This 
diversity in spectral and spatial sampling, within the same imaging step, presents novel 
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opportunities for optimization. Clinically useful images comparable to FT-IR imaging can be 
obtained significantly more rapidly, paving the way for this approach to be clinically translated 
for real-time pathology. 
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Figures and Tables 
 
Figure 11. Comparison of images and spectra obtained from FT-IR and DFIR instruments 
for two different patient samples. Images obtained using (A, E) FT-IR imaging data (B, F) 
DFIR imaging data using the absorbance at 1652 cm-1. The shaded region represents non-
normalized amide I intensity as gray scale image. Scale bar represents 500μm  (C, G) 
Average spectra obtained for FT-IR and DFIR images for background and tissue regions 
marked as B and T in the images from more than 5000 pixels over similar sized regions. (D, 
H) Spectra obtained at specific points in DFIR and FT-IR images at regions marked in 
images as red dots.  
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Figure 12. Imaging with DFIR instrumentation. (A) Image of myocardium collected at 
different pixel sizes. Every box is image area of 2.02 mm x 1.94 mm at shown pixel size to 
demonstrate the relative data sizes, obtained using the absorbance at 1656 cm-1 and plotted 
as color bar shown in (A).  (B) Absorption spectra show data collected at high speed (red) 
and low speed (black) on DFIR imaging instrument. (C) Time required to image plotted for 
various pixel sizes for the scan area of 2.5 mm2  
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Figure 13. Receiver operating characteristic (ROC) curves for classifiers. 
(i) Training on FT-IR imaging dataset (ii) Validation of FT-IR imaging 
based classifier on FT-IR imaging dataset (iii) Application of FT-IR 
imaging based classifier on DFIR imaging dataset (iv) Training on DFIR 
imaging dataset (v) Validation of DFIR imaging based classifier on DFIR 
imaging dataset (vi) Training of multiclass classifier on DFIR imaging 
dataset (vii) Validation of multiclass classifier on DFIR imaging dataset 
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Figure 14: Classification results shown for DFIR images of three different 
samples. (A, E, I) Classifier developed on FT-IR data. (B, F, J) Classifier 
developed on DFIR data. (C, G, K) Single metric identification of fibrosis. 
Red regions in all the IR colored images are fibrosis. Corresponding H&E 
images are shown in (D, H and L).  Red arrows indicate the regions 
identified by the pathologist as fibrosis.  
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Figure 15: Classification results of multiclass classifier on DFIR images of two different 
samples. (A, C) Classified images showing Fibrosis, Myocardium, Cell death, Blood and 
blood vessels and Non-tissue regions. (B,D) Corresponding H&E.  
 
Table 6: Confusion matrix for FT-IR imaging based classifier applied on 
DFIR imaging dataset 
  Ground Truth (Percent)   
Class Myocardium Fibrosis Total 
Unclassified 0.01 0 0 
Myocardium 96.14 18.65 87.43 
Fibrosis 3.85 81.35 12.57 
Total 100 100 100 
  Overall Accuracy 94.42% 
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Table 7: Confusion matrix for DFIR imaging based classifier applied on DFIR imaging 
dataset 
  Ground Truth  (Percent)   
Class Myocardium  Fibrosis  Total 
Unclassified 0 0 0 
Myocardium 91.4 12.22 82.5 
Fibrosis  8.6 87.78 17.5 
Total 100 100 100 
  Overall Accuracy 90.99% 
 
Table 8: Confusion matrix for specific band based detection  
  Ground Truth (Percent)   
Class Myocardium Fibrosis Total 
Myocardium 94.02 34.09 80.12 
Fibrosis 5.98 65.91 19.88 
Total 100 100 100 
  Overall Accuracy 87.50% 
 
 
Table 9: Confusion matrix for multiclass DFIR imaging based classifier 
  Ground Truth (Percent)   
Class Blood Cell death Fibrosis Myocardium Total 
Blood 57.93 10.52 21.85 1.97 10.95 
Cell death 0.03 3.67 0.03 0.01 0.08 
Fibrosis 33.05 8.05 66.29 6.61 24.49 
Myocardium 8.99 77.76 11.84 91.41 64.48 
Total 100 100 100 100 100 
    
Overall 
Accuracy 
82.87% 
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Figure 16: Optimal threshold identification. Shown here is the threshold identification for 
peak height ratio of 1236 cm-1 and 1542 cm-1 after fine tuning the ratio value threshold. 
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 Table 10. Metrics used in FT-IR imaging based classifier in the order of addition 
  
Metric type Feature 1  Feature 2 
Peak height ratio 1389 cm-1 1236 cm-1 
Peak area to height 
ratio 
1274 cm-1 to 1543 cm-
1 
1652 cm-1 
Peak height ratio 1239cm-1 1543 cm-1 
Peak height ratio 1339 cm-1 1543 cm-1 
Peak height ratio 1236 cm-1 1543 cm-1 
Peak height ratio 1389 cm-1 1452 cm-1 
Center of gravity 1482 cm-1 1594 cm-1 
Peak area to height 
ratio 
1324 cm-1 to 1358 cm-1 1652 cm-1 
Peak height ratio 1405 cm-1 1236 cm-1 
Peak area to height 
ratio 
1482 cm-1 to 1594 cm-
1 
1652 cm-1 
Peak height ratio 1027 cm-1 1236 cm-1 
Center of gravity 1048 cm-1 1070 cm-1 
Peak height ratio 1389 cm-1 1065 cm-1 
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Table 11: Metrics used in DFIR imaging based classifier in the order of addition, accuracy 
percentage is the accuracy obtained at each metric individually at optimized threshold 
values 
Metric type Feature 1  Feature 2  Accuracy (%) 
Peak height ratio 1038 cm-1 1542 cm-1 78.821 
Peak area to height ratio 
1482 cm-1 to 1590 
cm-1 
1038 cm-1 70.09 
Peak area to height ratio 
996 cm-1 to 1140 cm-
1  
1542 cm-1 79.712 
Peak height ratio 1236 cm-1 1542 cm-1 86.46 
Peak area to height ratio 
1482 cm-1 to 1590 
cm-1 
1236 cm-1 76.24 
Peak area to height ratio 
1182 cm-1 to 1290 
cm-1  
1542 cm-1 81.831 
Peak area to height ratio 
1482 cm-1 to 1710 
cm-1  
1236 cm-1 76.203 
Peak height ratio 1236 cm-1 1650 cm-1 85.185 
Peak area to height ratio 
1182 cm-1 to 1290 
cm-1 
1650 cm-1 80.239 
Peak height ratio 1074 cm-1 1650 cm-1 72.031 
Peak area to height ratio 
1482 cm-1 to 1590 
cm-1  
1020 cm-1 53.126 
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Table 12: Metrics used in multi-class DFIR imaging based classifier in the order of addition 
 
 
Metric type Feature 1  Feature 2 
Peak area to height ratio 1362 cm-1  to 1428 cm-1 1650 cm-1 
Peak area to height ratio 1482 cm-1  to 1590 cm-1 1038 cm-1 
Peak area to area ratio 1428 cm-1  to 1482 cm-1 1590 cm-1  to 1710 cm-1 
Peak area to height ratio 1482 cm-1 to 1710 cm-1 1464 cm-1 
Peak height ratio 1038 cm-1 1398 cm-1 
Peak area to height ratio 1482 cm-1 to 1710 cm-1 1236 cm-1 
Peak area to area ratio 1362 cm-1  to 1428 cm-1 1590 cm-1  to 1710 cm-1 
Peak height ratio 1236 cm-1 1464 cm-1 
Peak area to height ratio 1482 cm-1  to 1590 cm-1 1236 cm-1 
Peak height ratio 1482 cm-1 1650 cm-1 
Peak area to area ratio 1482 cm-1  to 1590 cm-1 1590 to 1710 cm-1 
Peak area to height ratio 1482 cm-1  to 1590 cm-1 1020 cm-1 
Peak area to area ratio 1362 cm-1  to 1482 cm-1 1590 cm-1  to 1710 cm-1 
Peak height ratio 1020 cm-1 1398 cm-1 
Peak area to height ratio 996 cm-1  to 1140 cm-1 1542 cm-1 
Peak area to area ratio 996 cm-1  to 1140 cm-1 1590 cm-1 to 1710 cm-1 
Peak area to height ratio 1362 cm-1  to 1428 cm-1 1020 cm-1 
Peak area to height ratio 1482 cm-1  to 1710 cm-1 1038 cm-1 
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SUMMARY 
In this work, we have developed infrared chemical imaging based approach towards digital 
pathology of cardiac biopsy samples. We first applied supervised Bayesian classification 
approach to identify lymphocytes, fibrosis in endocardium, fibrosis in myocardium, myocardium 
and endocardium with sensitivity of greater than 95% for all classes except endocardium at 90% 
specificity, while the sensitivity of endocardium was also at least 85%. This is the first 
demonstration of application of Fourier transform infrared spectroscopic imaging towards 
cardiac histology and is significant in establishing that the histological classes identified in 
endomyocardial biopsy samples have intrinsic chemical contrast. We also tested the performance 
of this classifier on low spatial resolution data collected at 25μm to assess if high speed detection 
could be achieved. While probability of detection was high for myocardium and average for 
lymphocytes, the classifier could not distinguish between other classes well.  
Following our previous attempts at developing a protocol for high speed histology, the next 
approach that we tested was using quantum cascade laser based discrete frequency instruments. 
This enabled us to collect data at high speed without compromising the spatial resolution. We 
first tested if the data collected in DFIR mode, which had lower signal to noise compared to FT-
IR data could be used for differentiation of histological classes based on spectral features. We 
observed that the unsupervised clustering detected similar regions in data collected on both DFIR 
and FT-IR instruments, indicating that the spectral differences that led to differentiation of 
classes in FT-IR were preserved in DFIR data despite low SNR.  
Next, we tested different approaches to develop high accuracy classification models for DFIR 
data. We first applied the classifiers built previously on FT-IR data on data collected in DFIR 
mode. This classifier performed well on discrete frequency data, confirming the premise that 
Bayesian classification can identify specific spectral features necessary and sufficient for 
identification of histological classes. We also developed a Bayesian classifier on DFIR data to 
assess the highest accuracy achieved in classification. Given the lower signal to noise ratio 
obtained in discrete frequency mode, it was expected that the accuracy would be lower for the 
classifier developed on DFIR data. This was confirmed by calculating the accuracy of final 
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classification, which dropped to about 91%. This accuracy lowered further when a multi-class 
classifier was developed on DF-IR data. We anticipate the issue of lower accuracy of classifiers 
developed on DF-IR data can be resolved with using a larger number of samples for training the 
classifiers, and applying noise correction algorithms.  
Finally, we were interested to see if the speed advantage of discrete frequency approach could be 
realized to its full potential by using a single metric based identification. We aimed to identify 
fibrosis in the myocardium which is indicative of tissue damage due to a number of factors such 
as immune response and myocardium damage and can be indicative of loss of function of heart 
muscle. We tested all the metrics utilized in Bayesian classifier for differentiation of fibrosis 
from myocardium, and chose the metric with highest accuracy of differentiation. This metric was 
found to achieve an accuracy of 87.5% for the differentiation of fibrosis from myocardium. 
While the use of discrete frequency mode as compared to FT-IR mode can lower the time 
required to image by 20-folds, this result can further reduce the time required by a factor of 10, 
making this technology practical and relevant on clinical scale. In the bigger picture, this work 
will be useful in developing probe based technology by direct implementation of results obtained 
from this work for a high speed detection of fibrosis. In addition, with high speed imaging being 
made possible by quantum cascade laser technology, this work contributes significantly towards 
high speed digital histopathology of cardiac tissue.   
 
